Avacta Group PLC Director's Dealing (8826W)
April 29 2016 - 10:04AM
UK Regulatory
TIDMAVCT
RNS Number : 8826W
Avacta Group PLC
29 April 2016
29 April 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director's Dealing
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that Craig Slater,
Chief Operating Officer of the Group, has today purchased 2,222
Ordinary Shares of 10p each in the Group at a price of 112.5 pence
per share.
Following this transaction, Mr Slater's total interest in the
Group is 349,452 Ordinary Shares of 10p each, representing
approximately 0.5% of Avacta's issued share capital.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
Numis Securities Limited Tel: +44 (0)
Michael Meade / Freddie Barnfield 207 260 1000
- Nominated Adviser www.numiscorp.com
James Black - Corporate Broking
WG Partners Tel: +44 (0)
David Wilson 203 705 9318
Nigel Barnes Tel: +44 (0)
Claes Spang 203 705 9217
www.wgpartners.co.uk
Media Enquiries Tel: +44 (0)
FTI Consulting 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on oncology and bleeding disorders as well as
several partnered development programmes. Avacta is commercialising
Affimer reagents through custom Affimer services to provide bespoke
solutions to customers and via a growing on-line catalogue of
Affimer reagents.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFISSLIAFIR
(END) Dow Jones Newswires
April 29, 2016 10:04 ET (14:04 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024